Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01209949 · ClinicalTrials.gov registry record · Phase 4

Assessment of Subjects' Efficacy and Experiences Using Adapalene BPO Gel in the Treatment of Acne Vulgaris

A Phase 4 study of Acne Vulgaris, sponsored by Galderma R&D.

Completed
Registry status
Phase 4
Development phase
30
Enrollment target
1
Study location

NCT01209949 is a Phase 4 study of Acne Vulgaris that has completed, run by Galderma R&D. The registered enrollment target is 30 participants, below the 275-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01209949, a Phase 4 study of Acne Vulgaris, has completed, sponsored by Galderma R&D.

COMPLETED
Registry status
Phase 4
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to assess subjects' experiences using Adapalene BPO gel to treat mild to moderate acne vulgaris using efficacy measurements, quality of life instruments, and video diaries.

Conditions Studied

Interventions

  • DRUG Adapalene 0.1% and Benzoyl Peroxide 2.5% gel

Study Locations (1)

Texas

  • Thomas J. Stephens and Associates - Carrollton

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2010-10
Est. Completion 2011-01
Phase Phase 4

Sponsor

Galderma R&D

158 total trials

What the Registry Record Tells You About NCT01209949

The ClinicalTrials.gov registry entry for NCT01209949 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 275-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (89% lower). The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Acne Vulgaris appearing as the primary indexed condition, and to 1 intervention - of which Adapalene 0.1% and Benzoyl Peroxide 2.5% gel is the first listed.

NCT01209949 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT01209949 about?

NCT01209949 is a clinical study titled "Assessment of Subjects' Efficacy and Experiences Using Adapalene BPO Gel in the Treatment of Acne Vulgaris". The purpose of this study is to assess subjects' experiences using Adapalene BPO gel to treat mild to moderate acne vulgaris using efficacy measurements, quality of life instruments, and video diaries.

What is the current status of trial NCT01209949?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2010-10. Estimated completion is 2011-01.

What conditions does trial NCT01209949 study?

This clinical trial studies the following conditions: Acne Vulgaris.

What interventions are being tested in trial NCT01209949?

The interventions under investigation include: Adapalene 0.1% and Benzoyl Peroxide 2.5% gel (DRUG).

Who is sponsoring clinical trial NCT01209949?

This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01209949 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Acne Vulgaris

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.